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Abstract 
Background: Methotrexate, a folate analogue, is the most commonly used disease-
modifying drug in the treatment of rheumatoid arthritis. However, high 
interindividual differences in drug response are present among RA patients. 
Research design and methods: In a group of 234 RA patients treated with MTX we 
investigated whether rs1650697 polymorphism in DHFR gene may have impact on 
MTX efficacy and/or adverse drug effects (ADEs). Relative DAS28 values (rDAS28) 
were used for MTX therapy estimation and all adverse drug events were recorded. 
Patients were genotyped for selected polymorphism by real-time PCR method. 
Results: According to the EULAR criteria after 6 months of MTX therapy 196 patients 
(83.8 %) were classified as responders, (25 (10.7 %) were good and 171 (73.1 %) 
were moderate) and 38 patients (16.2 %) as non-responders. ADEs were observed in 
55 patients (23.5 %).  
Conclusions: Our results showed that the presence of T allele might be protective 
against MTX hepatotoxicity measured by transaminaze levels (p=0.05). Furthermore, 
among patients who also received low-dose corticosteroids we have found a lower 
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1. Introduction  
Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic 
drug (DMARD) for the treatment of rheumatoid arthritis (RA) [1]. Low MTX doses 
used as either monotherapy or in combination with other drugs have a superior 
efficacy profile [2]. Despite MTX cost-effectiveness, clinical response to MTX varies 
widely [3]. Approximately 30-40% patients do not have a good response to MTX 
despite optimal dosing regimes [4]. Furthermore, some patients develop severe side 
effects such as cytopenias, gastrointestinal adverse effects (stomatitis, nausea), or 
abnormal liver function, which may limit its use and may result in additional health 
care costs [1]. These high interindividual differences in drug response gave rise to 
the need for prognostic markers in order to individualize and optimize therapy with 
these antirheumatic agents [5].  
The mechanisms of action of methotrexate are complex. Developed as a folic acid 
analogue, methotrexate inhibits purine and pyrimidine synthesis, which accounts for 
its efficacy in the therapy of cancer as well as for some of its toxicities [6]. It is 
considered that the main mechanism of MTX action is based on direct inhibition of 
dihydrofolatereductase (DHFR) and other key enzymes involved in folate metabolism 
[7]. DHFR inhibition leads to disruption of DNA replication and thus cell death [8].  
DHFR gene contains two alternative promoters: a major and a minor promoter. The 
major promoter is responsible for 99% transcription of the gene, whereas the minor 
promoter drives transcription of a non-coding RNA. This RNA harbors sequence of 
major DHFR gene promoter and has been found to fulfill regulatory function through 










rs1650697 (C35T) resides in a major promoter of DHFR gene and is associated with 
higher DHFR expression [10]. We have investigated whether this polymorphism may 
have impact on MTX efficacy and/or adverse drug effects (ADEs). 
 
2. Patients and methods 
234 patients with RA treated and prospectively followed at the Institute of 
Rheumatology (Faculty of Medicine, University of Belgrade, Serbia) were included in 
the study. Diagnosis for all patients was set according to the American College of 
Rheumatology (ACR) 1987 revised classification criteria for RA [11]. Physicians and 
patients were blinded to the genotypes and lab personnel were blinded to all clinical 
information throughout the study. Ethics Committee of the Institute of 
Rheumatology approved the study protocol and signed informed consent form was 
obtained from each patient involved in the study. Current and past treatment with 
MTX for at least 6 months was the main criterion for patient inclusion in the study. 
Patients receiving intraarticular corticosteroids were excluded from the study. Stable 
dosages of non-steroidal anti-inflammatory drugs (NSAIDs), low-dose corticosteroids 
(≤10mg/day), previous disease-modifying antirheumatic drugs other than MTX 
(DMARDs, Aurotherapy, Sulphasalazine, Chloraquine) and folic acid supplementation 
were allowed.  
Safety and clinical assessments were performed as our research group has 
previously reported [12]. To estimate the clinical response to MTX we have used 
EULAR (European League Against Rheumatism) response criteria and rDAS values 










good, moderate and poor responders. Good and moderate responders were 
considered to be responders and poor responders were considered to be 
nonresponders. rDAS was calculated for each patient using formula rDAS28 = 
(DAS280 – DAS281)/DAS280 (DAS280 represents DAS28 score at the beginning of 
MTX treatment and DAS281 represents DAS28 score after 6 months of therapy). 
Patient’s reports, results of routine laboratory measurements and physical 
examinations were used for ADEs recording as described in our previous study [14].  
In respect to defined criteria ADEs were defined as mild, moderate or severe [14].  
Severe ADEs required hospitalization and discontinuation of the MTX therapy.  
Molecular-genetic analyses were performed at the Institute of Human Genetics, 
Faculty of Dentistry, University of Belgrade, Serbia and Institute of Human Genetics, 
Faculty of Medicine, University of Belgrade. Salting out method was used to extract 
genomic DNA from peripheral blood leukocytes [15]. C35T polymorphism in DHFR 
gene was analyzed by real-time PCR method. We have used TaqMan probe 
(TaqMan® SNP Genotyping Assays), C_27863089_10, and each sample was analyzed 
in duplicate. The reaction mix volume was 25 µl and it included 12,5 µl of TaqMan 
Universal Master Mix, 0,625 µl of 40x stock, 10,875 µl of water and 1 µl of DNA. The 
reaction was conducted in LineGene K real-time PCR apparatus (Bioer Technology) 
under the following conditions: enzyme activation at 95ºC for 10 minutes; 40 cycles 
comprised of two steps (15 seconds of denaturation at 92ºC and primer binding, 
extension and DNA polymerization during 1 minute at 60 ºC) and final extension for 
1 minute at 72 ºC. VIC dye corresponded to allele 1 (T) while FAM corresponded to 










Student’s t-test or Mann-Whitney test (depending on homogeneity of variable 
distribution) for continuous variables and Chi-square test for dichotomous variables 
were used for analyzing the difference in patients, disease and treatment 
characteristic between responders and non-responders or those with and without 
ADEs. Differences in frequencies of genotypes between responders and non-
responders and patients with or without ADEs were analyzed by Chi-square test. 
rDAS28 difference across genotypes was assessed by ANOVA and Student’s t-test. 
When statistically significant results were observed we have used multiple logistic or 
linear regression analysis. All statistical analyzes were performed by SPSS version 
16.0 (SPSS Inc, Chicago, Illinois, USA). 
3. Results 
All patients included in the study were receiving MTX therapy for at least 6 months. 
The duration of the MTX treatment was 33.77 ± 34.20 months. 149 patients (63.7%) 
received low doses of corticosteroides, while 159 patients (67.9%) received folate 
suplements. Folate suplementation was introduced in the therapy in case of adverse 
effects appearance in doses recommended by physician. The main demographical 
and clinical characteristics of the patients are presented in Table 1.  
A significant decrease in DAS28 was obsereved at 6-month control (p < 0.0005). 
According to the EULAR response criteria, after 6 months of MTX therapy 196 
(83.8%) patients were classfied as responders (good 25 patients (10.7%) and 171 
(73.1%) moderate) and 38 (16.2%) patients as non-responders. MTX therapy 
response by EULAR criteria in regard to genotypes of rs1650697 polymorphism in 










MTX therapy response. Genotypes frequencies of analyzed polymorphism were not 
in Hardy-Weinberg equilibrium (HWE; tested using Pearsons’s chi-square test, 5% 
significance threshold).  This could be result of higher number of females than males 
in analyzed RA patients cohort compared with healthy population. Since no 
genotyping errors were observed and there is no recommendation for exclusion 
from the analyses of SNPs that are not HWE [16, 17], we did not investigate this 
further.  
Relative DAS28 values (rDAS28) ranged from  – 0.02 to 0.85 (0.34 ± 0.18).  In the 
group of 149 patients who received low-dose corticosteroids we have found 
statistically significant lower rDAS value in patients with CC genotype compared to 
patients with CT and TT genotypes (p=0.013), as shown in Table 3. To confirm 
obtained results we have used multiple linear regression analysis using as 
covariables gender, patients age, duration of the disease, folic acid supplementation, 
MTX dose and use of DMARDs other than MTX and result remained significant 
(ß=0.198, p=0.015). 
Adverse drug events were observed in 55 patients (23.5%). Most frequent ADEs 
were nausea (20 patients (8.5%)) and elevetaed transaminaze levels (24 patients 
(10.3%)), followed by bone marrow toxicity (9 patients (3.8%)), alopecia (7 
patients(3%)), stomatitis (4 patients (1.7%)), pneumonitis (2 patients (0.8%)) and 
caugh (1 patients(0.4%)). Severe ADEs were observed in 11 patients (4.7%) (bone 
marrow toxicity and pneumonitis) and they were forced to discontinue therapy.  
There was statistically significant difference between weekly MTX dose received by 










by the patients with no ADEs (11.98 ± 3.24 mg/week; p = 0.003). Association 
between the age of patients when RA simptoms appeared  and presence of ADEs has 
not been observed. Furthermore, we have obsereved no association of rs1650697 
polymorphism genotypes with overall ADEs. However, the presence of allele T (CT 
and TT genotypes) was protective against MTX hepatotoxicity (p=0.05). Distribution 
of genotypes in relation MTX hepatotoxicity is shown in Table 4. Results remained 
significant after multiple logistic regression analysis with gender, age of the patients, 
MTX dose, folic acid suplementation and use of DMARDs other than MTX as 
covariates (p=0.049, OR=0.356, CI:  0.127-0.993).  
4. Discussion 
One of the main goals of the MTX therapy in RA is DHFR protein inhibition. DHFR 
gene polymorphisms may influence its product activity and abundance. Hence, 
polymorphisms in this gene are attractive targets for the search of biomarkers that 
will allow clinicians to predict responses to MTX therapy. We have already explored 
several DHFR gene polymorphisms and reported influence of two analyzed 
polymorphisms on efficacy and toxicity of the MTX in RA patients [14, 18].  
There is very scarce information regarding rs1650697 polymorphism in RA patients 
treated with MTX available in the literature. This is a single nucleotide polymorphism 
located in a major promoter of DHFR gene [10]. It was noticed that T allele, which is 
one of the alleles present in 1b* haplotype may have influence on increased DHFR 
gene expression [10], but it is not clear if this polymorphism alone may influence 
level of DHFR expression. Wessels and associates have investigated a potential 










methotrexate in a group of 205 RA patients, but they have not found any association 
[19].  No association of this polymorphism with MTX response has been observed in 
a group of psoriatic arthritis patients [20]. 
Our study revealed a possible protective role of T allele against MTX hepatotoxicity 
measured by transaminaze levels in RA patients with elevated levels of transaminase 
after 6 months of methotrexate therapy in contrast to the results published by 
Wessels et al. [19].  According to the recent results [21] folates, regardless 
administration dose, protect against MTX toxicity and do not influence its efficacy. 
Unfortunately, for some RA patients folate supplementation is not sufficient against 
MTX toxicity. These patients have to be recognized and included in alternative 
therapy protocols. In order to accomplish this, identification of genetic 
polymorphisms specific for those patients is necessary. DHFR protein levels rapidly 
increase upon exposure to methotrexate due to increase of DHFR translation, 
provoked by the drug action [22] and there are no evidences that MTX could 
influence DHFR protein levels through changes of DHFR gene expression. 
Consequently, we did not analyze the expression of the DFHR gene before and after 
MTX treatment. Our findings may contribute to results of other authors [10] and 
hypothesis that allele T is responsible for higher DHFR gene expression. Namely, in a 
the direct inhibitory action of the drug on the protein, like in case of MTX and DHFR 
protein, increased activity or level of the protein may result in diminished drug 
effects in a sense of its reduced efficacy and toxicity. Our results regarding analyzed 
polymorphism and MTX hepatotoxicity contradict to results of some previously 










total analyzed cohort of the RA patients is small and for the final conclusions 
additional investigations are necessary. In accordance with previous studies we 
found no association of C35T polymorphism with methotrexate efficacy according to 
EULAR response criteria in RA patients, but our results showed lower rDAS value in 
carriers of CC genotype in a group of patients receiving MTX therapy in combination 
with low-dose corticosteroids. Lower rDAS values may indicate less favorable 
response to MTX. There are only several studies that investigated possible 
interactions between MTX and corticosteroids, but results are controversial. In the 
study on the C6-glioma cells it has been shown that corticosteroid dexametasone 
induces high doses MTX resistence [23]. According to study on rats [24] 
administration of corticosteroids reduce biliary clearance of MTX and consequently 
contribute to its hepatotoxic effects, while in study on 154 RA patients no interaction 
between those drugs has been confirmed, although corticosteroid administration 
significantly delayed the time of MTX ADEs appearance [25]. In a group of 33 RA 
patients Lafforgue and associates [26] observed an influence of long-term 
corticosteroids administration on MTX pharmacokinetics. Association of MTX and 
corticosteroids administration with hepatotoxicity in the children brain tumor 
therapy has been reported, but again no obvious drug-drug interaction has been 
proven [27]. It is important to emphasize that rDAS value does not represent 
common measure of MTX efficacy, but reflects changes in disease activity. Group of 
patients receiving corticosteroids in cohort analyzed in our study had more active 
disease at the beginning of the therapy and it is possible that this resulted in less 
favorable MTX response in CC genotype carriers. Additionally, our patients had more 










studies. Obviously, the results so far are not sufficient for final conclusions and 
considering therapy protocols that often include MTX and corticosteroids and new 
studies which will finally explain if there is an interaction between these potent 
antirheumatic drugs are necessary. Further studies in larger patient groups are 
necessary to confirm the relationship between the analyzed polymorphism and MTX 
treatment response and reveal its possible role in relation to low-dose 
corticosteroids treatment in rheumatoid arthritis.  
5. Conclusion  
In conclusion, our results indicated a possible protective role of T allele against 
hepatotoxicity in RA patients. No association of C35T polymorphism with 
methotrexate efficacy in RA patients was found, but our results showed lower rDAS 
value in carriers of CC genotype in a group of patients receiving MTX therapy in 
combination with low-dose corticosteroids. Lower rDAS values may indicate less 
favorable response to MTX. 
Further studies in larger patient groups are necessary to confirm the relationship 
between the analyzed polymorphism and MTX treatment response and reveal its 
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Table 1. Demographical and clinical characteristics of the RA patients analyzed in the 
study; DAS28 0 represents DAS28 values at the beginning of therapy, DAS28 
represents DAS28 values after six months of therapy.  
Table 2. MTX therapy response by EULAR criteria in regard to DHFR gene rs1650697 
polymorphism genotypes. 
Table 3. rDAS28 values in relation to DHFR gene rs1650697 polymorphism genotypes 
of RA patients treated with MTX therapy in combination with low-dose 
corticosteroids. 












Table 1. Demographical and clinical characteristics of the RA patients analyzed in the 
study; DAS28 0 represents DAS28 values at the beginning of therapy, DAS28  





characteristic value, range (mean)/n (%) 
female/male 184 (78.6)/50 (21.4) 
mean age (years) 20-84 (57.49±10.62) 
duration of the disease (months) 6-240 (46.75±41.06) 
weekly MTX dose (mg) 7.5-20.0 (11.70±3.20) 
low dose corticosteroids mg/day ≤10 (6.20±4.81) 
DAS28 0 5.10-9.14 (7.50±0.86) 























CC 113 (48.29) 28 (11.97) 141 (60.26) 
0.177 CT 38 (16.24) 5 (2.14) 43 (18.38) 





























Table 3. rDAS28 values in relation to DHFR gene rs1650697 polymorphism genotypes  




Genotype Number of patients, (%) rDAS28 values p 
CC 92 (61.7) 0.295±0.166 
0.013 










Table 4. Hepatotoxicity in relation to DHFR gene rs1650697 polymorphism 
genotypes 
 
Genotype No hepatotoxicity, n (%) Hepatotoxicity, n (%) p 
CC 122 (52.13) 19 (8.12)              
             0.05 CT+TT 88 (37.61) 5 (2.14) 
